Comparative Pharmacology
Head-to-head clinical analysis: ACCUTANE versus AFAXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCUTANE versus AFAXIN.
ACCUTANE vs AFAXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Retinoid that reduces sebum production, normalizes follicular keratinization, and decreases Propionibacterium acnes growth by binding to nuclear retinoic acid receptors, altering gene expression.
Selective inhibitor of the sodium-dependent serotonin reuptake transporter (SERT), increasing serotonin levels in the synaptic cleft.
Isotretinoin 0.5-1 mg/kg/day orally in 2 divided doses for 15-20 weeks.
500 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life of isotretinoin is 10-20 hours. The half-life of the major metabolite, 4-oxo-isotretinoin, is 11-50 hours. The long half-life of the metabolite may contribute to sustained clinical effects.
Clinical Note
moderateVenlafaxine + Desmopressin
"The risk or severity of adverse effects can be increased when Venlafaxine is combined with Desmopressin."
Clinical Note
moderateDesvenlafaxine + Desmopressin
"The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Desmopressin."
Clinical Note
moderateDesvenlafaxine + Haloperidol
"The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Haloperidol."
Clinical Note
moderateTerminal elimination half-life is 12-15 hours in healthy adults, allowing twice-daily dosing; prolonged in renal impairment (up to 30 hours).
Renal and biliary: approximately equal amounts of metabolites are excreted in urine and feces. Unchanged drug is not excreted. Major metabolites: 4-oxo-isotretinoin, tretinoin, 4-oxo-tretinoin. Renal excretion of metabolites accounts for ~65-83% of the dose; fecal excretion accounts for the remainder.
Renal excretion accounts for approximately 60-70% of the administered dose as unchanged drug; biliary/fecal elimination accounts for 20-25% with the remainder as metabolites.
Category C
Category C
Retinoid
Retinoid
Venlafaxine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Venlafaxine."